Foresite Capital Management II’s Regenxbio RGNX Stock Holding History

Foresite Capital Management II’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-47,443	Closed	-$1.54M	–	5
2020 Q1	$1.54M	Buy	+47,443	New	+$1.98M	0.36%	6
2016 Q3	–	Sell	-156,741	Closed	-$1.25M	–	13
2016 Q2	$1.25M	Hold	156,741	–	–	0.86%	14
2016 Q1	$1.69M	Hold	156,741	–	–	0.83%	17
2015 Q4	$2.6M	Hold	156,741	–	–	0.87%	19
2015 Q3	$3.45M	Buy	+156,741	New	+$4M	1.05%	18

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foresite Capital Management II's RGNX Position: Q2 2020 in Review

Foresite Capital Management II sold out of Regenxbio (RGNX) in Q2 2020, closing a stake of 47,443 shares — an estimated $1.54M sold.

Foresite Capital Management II first reported a position in RGNX in Q3 2015 and held it in 5 quarters. The position peaked at $3.45M in Q3 2015. 179 funds tracked by Wall St. Rank hold RGNX as of Q2 2020.

Foresite Capital Management II reported no remaining Regenxbio position as of Q2 2020 after selling out during the quarter.
Foresite Capital Management II sold 47,443 Regenxbio shares in Q2 2020, an estimated $1.54M.
Foresite Capital Management II first reported a position in Regenxbio in Q3 2015 and held it in 5 quarters.
Foresite Capital Management II's Regenxbio position peaked at $3.45M in Q3 2015.
179 funds tracked by Wall St. Rank held Regenxbio as of Q2 2020.

Based on Foresite Capital Management II's 13F filing for Q2 2020, filed 13 Aug 2020.